EQRx is a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at radically lower prices. We’re purpose-built, at scale, with a growing portfolio of medicines in development in high-cost drug categories and emerging partnerships with leading payers and providers.



EQRx to Accelerate Growth with $1.8 Billion Raise through Proposed Combination with CM Life Sciences III 

EQRx, Inc., and CM Life Sciences III, Inc. (NASDAQ: CMLTU), a life science-focused special purpose acquisition company, or SPAC, sponsored by affiliates of Casdin Capital, LLC and Corvex Management LP, announced that they have entered into a definitive business combination agreement. The transaction is expected to provide up to $1.8 billion in cash proceeds to EQRx, expanding the cash on its balance sheet to approximately $2.0 billion at closing.


In less than two years since launch, we’ve already made major steps in advancing our mission of addressing the rising cost of medicine. Learn more.